menu
    • menu
    [{"orgOrder":0,"company":"Ipca Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ipca Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipca Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipca Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Ipca Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ipca Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipca Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipca Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Ipca Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ipca Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipca Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipca Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Ipca Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ipca Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipca Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipca Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Bright Future Pharma Lab","sponsor":"Chinese University of Hong Kong","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bright Future Pharma Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bright Future Pharma Lab \/ Chinese University of Hong Kong","highestDevelopmentStatusID":"6","companyTruncated":"Bright Future Pharma Lab \/ Chinese University of Hong Kong"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Yiling Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yiling Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Yiling Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Pharmtechnology","sponsor":"ClinPharmInvest","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmtechnology \/ ClinPharmInvest","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ ClinPharmInvest"},{"orgOrder":0,"company":"University of Louisville","sponsor":"Thoratec Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Louisville","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Louisville \/ Thoratec Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University of Louisville \/ Thoratec Corporation"},{"orgOrder":0,"company":"National Institute of Diabetes and Digestive and Kidney Diseases","sponsor":"Boehringer Ingelheim GmbH | Merck & Co | Polycystic Kidney Disease Foundation | The University of Pittsburgh School of Medicine | Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Nephrology","graph2":"Phase III","graph3":"National Institute of Diabetes and Digestive and Kidney Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Diabetes and Digestive and Kidney Diseases \/ Boehringer Ingelheim GmbH | Merck & Co | Polycystic Kidney Disease Foundation | The University of Pittsburgh School of Medicine | Washington University School of Medicine","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Diabetes and Digestive and Kidney Diseases \/ Boehringer Ingelheim GmbH | Merck & Co | Polycystic Kidney Disease Foundation | The University of Pittsburgh School of Medicine | Washington University School of Medicine"},{"orgOrder":0,"company":"Ascension Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Ascension Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascension Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ascension Health \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Lupus Research Alliance","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Immunology","graph2":"Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Northwell Health \/ Lupus Research Alliance","highestDevelopmentStatusID":"8","companyTruncated":"Northwell Health \/ Lupus Research Alliance"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Aminu Kano Teaching Hospital | Frederick National Laboratory | Brigham and Women's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University Medical Center \/ National Institute of Diabetes and Digestive and Kidney Diseases | Aminu Kano Teaching Hospital | Frederick National Laboratory | Brigham and Women's Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Vanderbilt University Medical Center \/ National Institute of Diabetes and Digestive and Kidney Diseases | Aminu Kano Teaching Hospital | Frederick National Laboratory | Brigham and Women's Hospital"},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"PharmaKinetics Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Par Pharmaceutical \/ PharmaKinetics Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Par Pharmaceutical \/ PharmaKinetics Laboratories"},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"PharmaKinetics Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Par Pharmaceutical \/ PharmaKinetics Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Par Pharmaceutical \/ PharmaKinetics Laboratories"},{"orgOrder":0,"company":"ALMATICA PHARMA INC","sponsor":"TWi Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ALMATICA PHARMA INC","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"ALMATICA PHARMA INC \/ TWi Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"ALMATICA PHARMA INC \/ TWi Pharmaceuticals"},{"orgOrder":0,"company":"Alvogen","sponsor":"AZTIQ PHARMA","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alvogen","amount2":0.34999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Alvogen \/ AZTIQ PHARMA","highestDevelopmentStatusID":"15","companyTruncated":"Alvogen \/ AZTIQ PHARMA"},{"orgOrder":0,"company":"Uptal Patel","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital | The Emmes Company, LLC | University of Rochester | OpAns, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Uptal Patel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uptal Patel \/ Gansu Provincial Maternal and Child Health Care Hospital | The Emmes Company, LLC | University of Rochester | OpAns, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Uptal Patel \/ Gansu Provincial Maternal and Child Health Care Hospital | The Emmes Company, LLC | University of Rochester | OpAns, LLC"}]

    Find Clinical Drug Pipeline Developments & Deals for Lisinopril

    Menu

    Lisinopril

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ALMATICA PHARMA INC

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            ALMATICA PHARMA INC

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : TWi Pharmaceuticals

                            Deal Size : $38.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bora Acquires Six US Brand Product Licenses, Rights

                            Details : Through the acquisition, Bora will utilize Almatica's generic pharmaceutical products, including Zestril (lisinopril), an oral tablet used for treating hypertension, for commercialization purposes.

                            Product Name : Zestril

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 18, 2023

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : TWi Pharmaceuticals

                            Deal Size : $38.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pharmtechnology

                            Belarus arrow
                            OTS 2025
                            Not Confirmed

                            Pharmtechnology

                            Belarus arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : ClinPharmInvest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Condit...

                            Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 30, 2021

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : ClinPharmInvest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alvogen

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Alvogen

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : AZTIQ PHARMA

                            Deal Size : $350.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Aztiq Buys 17% Stake in Alvogen US

                            Details : Zestril (lisinopril) belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily. Zestril is used to treat high blood pressure (hypertension) in adults and children who are at least 6 years old.

                            Product Name : Zestril

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 30, 2021

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : AZTIQ PHARMA

                            Deal Size : $350.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Yiling Pharmaceutical

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Yiling Pharmaceutical

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Preparation Products of Yiling Pharma Approved by FDA for Launch in the US Market

                            Details : The announcement showed that Lisinopril Tablets are mainly used for the treatment of essential hypertension (EH) and renal vascular hypertension (RVH) and were originally researched and developed by Astrazeneca and approved for launch in the United State...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 19, 2020

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Northwell Health

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Northwell Health

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Lupus Research Alliance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Centrally Acting ACE Inhibition in SLE

                            Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lupus Erythematosus, Systemic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 24, 2020

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Lupus Research Alliance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bright Future Pharma Lab

                            Hong Kong arrow
                            OTS 2025
                            Not Confirmed

                            Bright Future Pharma Lab

                            Hong Kong arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Chinese University of Hong Kong

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Bioequivalence Study on Two Lisinopril Tablets 20mg Formulations

                            Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 26, 2018

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Chinese University of Hong Kong

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ascension Health

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Ascension Health

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.

                            Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Drug-induced Cardiomyopathies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 08, 2018

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Vanderbilt University Medical Center

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Vanderbilt University Medical Center

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : National Institute of Diabetes and Digestive and Kidney Diseases | Aminu Kano Teaching Hospital | Frederick National Laboratory | Brigham and Women's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria

                            Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 28, 2017

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : National Institute of Diabetes and Digestive and Kidney Diseases | Aminu Kano Teaching Hospital | Frederick National Laboratory | Brigham and Women's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Dexa Medica

                            Indonesia arrow
                            OTS 2025
                            Not Confirmed

                            Dexa Medica

                            Indonesia arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Two Formulations of 10 mg Lisinopril Tablet Under Fasting Condition

                            Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 05, 2013

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            National Institute of Diabetes and Digestive and Kidney Diseases

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            National Institute of Diabetes and Digestive and Kidney Diseases

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Boehringer Ingelheim GmbH | Merck & Co | Polycystic Kidney Disease Foundation | The University of Pittsburgh School of Medicine | Washington University School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HALT Progression of Polycystic Kidney Disease Study B

                            Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polycystic Kidney Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 25, 2013

                            Lead Product(s) : Lisinopril

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Boehringer Ingelheim GmbH | Merck & Co | Polycystic Kidney Disease Foundation | The University of Pittsburgh School of Medicine | Washington University School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth